- Design Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from ChinaPlus, news about Enhertu and Tecentriq. 💪 Design Therapeutics shares Phase 1/2 data in Friedreich's ataxia: The California biotech’s DT-216P2 given at 1 mg/kg led to an average 6.4-point improve…Endpoints · 2mo ago↗ source
- Merck's ADC sac-TMT gets its first global Phase 3 win ahead of scheduleAn experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the pat…Endpoints · 2mo ago↗ source
- The Supreme Court won't take up drugmakers' IRA casesThe Supreme Court says it won’t wade into the pharma industry’s yearslong legal battle over Medicare drug price negotiations. The justices declined to review multiple cases brought by AstraZeneca…